Homoharringtonine May be ‘Better Alternative’ to Etoposide In Pediatric AML

Use of homoharringtonine (HHT) may result in improved responses among patients with pediatric acute myeloid leukemia (AML) compared with etoposide-based induction therapy, according to findings from a study published in the Journal of Clinical Oncology.

Read more: https://www.cancernetwork.com/view/homoharringtonine-may-be-better-alternative-to-etoposide-in-pediatric-aml